Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SkinBioTherapeutics ( (GB:SBTX) ) has shared an announcement.
SkinBioTherapeutics, which also pursues acquisitions in complementary skincare and cosmetic fields to expand distribution, geography and manufacturing, has been listed on AIM since 2017 and operates from Newcastle. The group aims to leverage its platform technologies across multiple skin health pillars while using consolidation to broaden routes to market for its in-house products.
The company has appointed new Non-Executive Director and Audit Committee Chair Alyson Levett to oversee an ongoing investigation process on behalf of the board. It has also engaged FRP Advisory to conduct an independent forensic review into previously outlined matters, aiming to expedite completion so that interim results can be issued with confidence and management can refocus on running and growing the business, with further updates to follow as appropriate.
The most recent analyst rating on (GB:SBTX) stock is a Hold with a £6.00 price target. To see the full list of analyst forecasts on SkinBioTherapeutics stock, see the GB:SBTX Stock Forecast page.
Spark’s Take on GB:SBTX Stock
According to Spark, TipRanks’ AI Analyst, GB:SBTX is a Neutral.
The score is held down primarily by weak technical conditions (deep downtrend and very poor momentum) and ongoing losses with negative cash flows. These are partially offset by strong revenue growth and a relatively conservative balance sheet.
To see Spark’s full report on GB:SBTX stock, click here.
More about SkinBioTherapeutics
SkinBioTherapeutics is a UK-based life science company focused on skin health, built around its proprietary SkinBiotix platform derived from research at the University of Manchester. Its core activities span cosmetic skincare and gut-skin axis food supplements, marketed under brands such as SkinBiotix, AxisBiotix and Croda-partnered Zenakine, with products sold direct-to-consumer, via Amazon and through selected Superdrug stores.
Average Trading Volume: 3,867,758
Technical Sentiment Signal: Sell
Current Market Cap: £15.55M
For a thorough assessment of SBTX stock, go to TipRanks’ Stock Analysis page.